KDR and hypertensive disorder: Thus, the Gremlin-1/VEGFR2 axis is considered as a promising therapeutic target that needs to be further studied, due to the fact that the currently approved VEGFR2 inhibitors are associated with side effects, such as hypertension, hypothyroidism, and coagulation disorders [58].